Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Oct 1;47(10):1846-1854.
doi: 10.2337/dc24-1003.

Effect of SARS-CoV-2 Infection on Incident Diabetes by Viral Variant: Findings From the National COVID Cohort Collaborative (N3C)

Affiliations

Effect of SARS-CoV-2 Infection on Incident Diabetes by Viral Variant: Findings From the National COVID Cohort Collaborative (N3C)

Rachel Wong et al. Diabetes Care. .

Abstract

Objective: The coronavirus 2019 (COVID-19) pandemic has evolved over time by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant, disease severity, treatment, and prevention. There is evidence of an elevated risk of incident diabetes after COVID-19; our objective was to evaluate whether this association is consistent across time and with contemporary viral variants.

Research design and methods: We conducted a retrospective cohort study using National COVID Cohort Collaborative (N3C) data to evaluate incident diabetes risk among COVID-positive adults compared with COVID-negative patients or control patients with acute respiratory illness (ARI). Cohorts were weighted on demographics, data site, and Charlson comorbidity index score. The primary outcome was the cumulative incidence ratio (CIR) of incident diabetes for each viral variant era.

Results: Risk of incident diabetes 1 year after COVID-19 was increased for patients with any viral variant compared with COVID-negative control patients (ancestral CIR 1.16 [95% CI 1.12-1.21]; Alpha CIR 1.14 [95% CI 1.11-1.17]; Delta CIR 1.17 [95% CI 1.13-1.21]; Omicron CIR 1.13 [95% CI 1.10-1.17]) and control patients with ARI (ancestral CIR 1.17 [95% CI 1.11-1.22]; Alpha CIR 1.14 [95% CI 1.09-1.19]; Delta CIR 1.18 [95% CI 1.11-1.26]; Omicron CIR 1.20 [95% CI 1.13-1.27]). There was latency in the timing of incident diabetes risk with the Omicron variant; in contrast with other variants, the risk presented after 180 days.

Conclusions: Incident diabetes risk after COVID-19 was similar across different SARS-CoV-2 variants. However, there was greater latency in diabetes onset in the Omicron variant era.

PubMed Disclaimer

Conflict of interest statement

Duality of Interest. T.S. receives salary support from the Center for Pharmacoepidemiology (current members GlaxoSmithKline, UCB BioSciences, Takeda Pharmaceuticals, AbbVie, Boehringer Ingelheim, Astellas, and Sarepta) and owns stock in Novartis, Roche, and Novo Nordisk. J.B. has received grant support from Bayer, Boehringer Ingelheim, Carmot, Corcept, Dexcom, Eli Lilly, Insulet, MannKind, Novo Nordisk, and vTv Therapeutics; consulting contracts from Alkahest, Altimmune, Anji, Aqua Medical, Inc., AstraZeneca, Boehringer Ingelheim, CeQur, Corcept Therapeutics, Dasman Diabetes Center (Kuwait), Eli Lilly, Embecta, Fortress Biotech, GentiBio, Glyscend, Insulet, Mediflix, Medscape, Mellitus Health, Metsera, Moderna, Novo Nordisk, Pendulum Therapeutics, Praetego, ReachMD, Stability Health, Tandem, Terns, Inc., and Vertex; expert witness engagement by Medtronic MiniMed; and stock options from Glyscend, Mellitus Health, Pendulum Therapeutics, Praetego, and Stability Health. No other potential conflicts of interest relevant to this article were reported.

Figures

None
Graphical abstract
Figure 1
Figure 1
Cumulative incidence and CIR of diabetes in adults after COVID-19 compared with COVID-negative and ARI control patients by COVID variant and time period: ancestral (A), Alpha (B), Delta (C), and Omicron (D). NA, not applicable.
Figure 2
Figure 2
Results of studies comparing risk of incident diabetes in adult COVID-positive vs. COVID-negative control groups (12,13,15,17,18,41–43). CIR indicates CIR at 1 year from index date. Pietropaolo et al. (42) reported odds ratios (ORs) as risk of incident diabetes in COVID-negative vs. COVID-positive patients. SHR, sub-HR; T1D, type 1 diabetes; T2D, type 2 diabetes.
Figure 3
Figure 3
Results of studies comparing risk of incident diabetes in adult COVID-positive vs. ARI control groups (15,18–21,41). CIR indicates CIR at 1 year from index date, and mild, moderate (mod), and severe indicate severity of illness. IRR, incidence rate ratio; OR, odds ratio; RR, rate ratio; SHR, sub-HR; T1D, type 1 diabetes; T2D, type 2 diabetes.

References

    1. GBD 2021 Diabetes Collaborators . Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021. Lancet 2023;402:203–234 - PMC - PubMed
    1. Khan MAB, Hashim MJ, King JK, Govender RD, Mustafa H, Al Kaabi J. Epidemiology of type 2 diabetes: global burden of disease and forecasted trends. J Epidemiol Glob Health 2020;10:107–111 - PMC - PubMed
    1. Wong R, Lam E, Bramante CT, et al. . Does COVID-19 infection increase the risk of diabetes? Current evidence. Curr Diab Rep 2023;23:207–216 - PMC - PubMed
    1. Banerjee M, Pal R, Dutta S. Risk of incident diabetes post-COVID-19: a systematic review and meta-analysis. Prim Care Diabetes 2022;16:591–593 - PMC - PubMed
    1. Lai H, Yang M, Sun M, et al. . Risk of incident diabetes after COVID-19 infection: a systematic review and meta-analysis. Metabolism 2022;137:155330. - PMC - PubMed

Supplementary concepts